Cognitive function in a randomized trial of evolocumab

Robert P. Giugliano, Marc S. Sabatine, Brian R. Ott, Gary Wittert

Research output: Contribution to journalArticlepeer-review

110 Citations (Scopus)


Findings from clinical trials of proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result from their use are associated with cognitive deficits.
Original languageEnglish
JournalNew England Journal of Medicine
Issue number20
Publication statusPublished or Issued - 16 Nov 2017

ASJC Scopus subject areas

  • Medicine(all)

Cite this